Charles Schwab Investment Management Inc Entrada Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $527 Billion
- Q4 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 197,127 shares of TRDA stock, worth $2.55 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
197,127
Previous 185,984
5.99%
Holding current value
$2.55 Million
Previous $2.97 Million
14.63%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding TRDA
# of Institutions
104Shares Held
28.1MCall Options Held
34.5KPut Options Held
16.4K-
Baker Bros. Advisors LP New York, NY4.87MShares$63 Million0.83% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.43MShares$57.3 Million48.7% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$57 Million28.09% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.05MShares$39.5 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X01.71MShares$22.1 Million0.01% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $406M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...